Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients

Intensive Care Medicine

Volumn 33, Issue 10, 2007, Pages 1694-1703

  Trof, R J ^a   Beishuizen, A ^a   Debets Ossenkopp, Y J ^a   Girbes, A R J ^a   Groeneveld, A B J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antifungal therapy; Invasive pulmonary aspergillosis; Non neutropenic critically ill; Serological markers

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CASPOFUNGIN; ECHINOCANDIN; GALACTOMANNAN; ITRACONAZOLE; METHYLTESTOSTERONE; MICAFUNGIN; MIDAZOLAM; POSACONAZOLE; VORICONAZOLE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; CYTOPATHOLOGY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; HISTOPATHOLOGY; HUMAN; IMMUNOREGULATION; INCIDENCE; INTENSIVE CARE UNIT; LABORATORY TEST; LIVER DISEASE; LUNG ASPERGILLOSIS; MYCOSIS; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; ASPERGILLOSIS; ASPERGILLUS; BETA-GLUCANS; CRITICAL ILLNESS; DNA, FUNGAL; DRUG THERAPY, COMBINATION; HUMANS; INTENSIVE CARE UNITS; LUNG DISEASES, FUNGAL; MANNANS; OPPORTUNISTIC INFECTIONS; POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 34748922865     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0791-z     Document Type: Review

References (116)

1. Bulpa PA, Dive AM, Garrino MG, Delos MA, Gonzalez MR, Evrard PA, Glupczynski Y, Installe EJ (2001) Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 27:59-67
2. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F, Nolla-Salas J, Iruretagoyena JR, Barcenilla F (2005) Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 9:R191-R199
3. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van WE (2004) Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170:621-625
4. Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F (2004) Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg 59:251-257
5. Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D (2004) Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 56:269-276
6. Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, Vogelaers D (2006) Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 10:R31
7. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, Morrison VA, Pappas P, Hiemenz JW, Stevens DA (2001). The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 33:1824-1833
8. Sessa A, Meroni M, Battini G, Pitingolo F, Giordano F, Marks M, Casella P (1996) Nosocomial outbreak of Aspergillus fumigatus infection among patients in a renal unit? Nephrol Dial Transplant 11:1322-1324
9. Anaissie EJ, Costa SF (2001) Nosocomial aspergillosis is waterborne. Clin Infect Dis 33:1546-1548
10. Anaissie EJ, Stratton SL, Dignani MC, Summerbell RC, Rex JH, Monson TP, Spencer T, Kasai M, Francesconi A, Walsh TJ (2002) Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 34:780-789
11. Reichenberger F, Habicht JM, Gratwohl A, Tamm M (2002) Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 19:743-755
12. Cenci E, Perito S, Enssle KH, Mosci P, Latge JP, Romani L, Bistoni F (1997) Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 65:564-570
13. Cenci E, Mencacci A, Fe DC, Del SG, Mosci P, Montagnoli C, Bacci A, Romani L (1998) Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 178:1750-1760
14. Cenci E, Mencacci A, Del SG, Bacci A, Montagnoli C, d'Ostiani CF, Mosci P, Bachmann M, Bistoni F, Kopf M, Romani L (1999) Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 180:1957-1968
15. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L (2000) T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 165:381-388
16. Lederer JA, Rodrick ML, Mannick JA (1999) The effects of injury on the adaptive immune response. Shock 11:153-159
17. Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman KH (2003) Immunoparalysis as a cause for invasive aspergillosis? Intensive Care Med 29:2068-2071
18. Maertens J, Vrebos M, Boogaerts M (2001) Assessing risk factors for systemic fungal infections. Eur J Cancer Care 10:56-62
19. Kwoun MO, Ling PR, Lydon E, Imrich A, Qu Z, Palombo J, Bistrian BR (1997) Immunologic effects of acute hyperglycemia in nondiabetic rats. J Parenter Enteral Nutr 21:91-95
20. Diamond RD (1983) Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones. J Infect Dis 147:160
21. Ng TT, Robson GD, Denning DW (1994) Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 140:2475-2479
22. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ (1993) Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 61:4870-4877
23. Schaffner A (1985) Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J Clin Invest 76:1755-1764
24. Crean JM, Niederman MS, Fein AM, Feinsilver SH (1992) Rapidly progressive respiratory failure due to Aspergillus pneumonia: a complication of short-term corticosteroid therapy. Crit Care Med 20:148-150
25. Pittet D, Huguenin T, Dharan S, Sztajzel-Boissard J, Ducel G, Thorens JB, Auckenthaler R, Chevrolet JC (1996) Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154:541-544
26. Rello J, Esandi ME, Mariscal D, Gallego M, Domingo C, Valles J (1998) Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis 26:1473-1475
27. Maki DG (1989) Risk factors for nosocomial infection in intensive care. 'Devices vs nature' and goals for the next decade. Arch Intern Med 149:30-35
28. Ader F, Nseir S, Le BR, Leroy S, Tillie-Leblond I, Marquette CH, Durocher A (2005) Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 11:427-429
29. Ader F, Nseir S, Guery B, Tillie-Leblond I (2006) Acute invasive pulmonary aspergillosis in chronic lung disease - a review. Rev Mal Respir 23:S11-20
30. Chen KY, Ko SC, Hsueh PR, Luh KT, Yang PC (2001) Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest 120:177-184
31. Khasawneh F, Mohamad T, Moughrabieh MK, Lai Z, Ager J, Soubani AO (2006) Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome. J Crit Care 21:322-327
32. Soubani AO, Khanchandani G, Ahmed HP (2004) Clinical significance of lower respiratory tract Aspergillus culture in elderly hospitalized patients. Eur J Clin Microbiol Infect Dis 23:491-494
33. Vandewoude KH, Vogelaers D, Blot SI (2006) Aspergillosis in the ICU - the new 21st century problem? Med Mycol 44:S71-76
34. Prodanovic H, Cracco C, Massard J, Barrault C, Thabut D, Duguet A, Datry A, Derenne JP, Poynard T, Similowski T (2007) Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series. BMC Gastroenterol 7:2
35. Sahlen AO, Suvarna SK, Wilkie ME (2004) A case of invasive pulmonary aspergillosis in renal failure. Nephrol Dial Transplant 19:2687
36. ter Maaten JC, Golding RP, Strack van Schijndel RJ, Thijs LG (1995) Disseminated aspergillosis after near-drowning. Neth J Med 47:21-24
37. Vieira DF, Van Saene HK, Miranda DR (1984) Invasive pulmonary aspergillosis after near-drowning. Intensive Care Med 10:203-204
38. Leroy P, Smismans A, Seute T (2006) Invasive pulmonary and central nervous system aspergillosis after near-drowning of a child: case report and review of the literature. Pediatrics 118:e509-e513
39. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14
40. Levy H, Horak DA, Tegtmeier BR, Yokota SB, Forman SJ (1992) The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis. Respir Med 86:243-248
41. Cahill BC, Hibbs JR, Savik K, Juni BA, Dosland BM, Edin-Stibbe C, Hertz MI (1997). Aspergillus airway colonization and invasive disease after lung transplantation. Chest 112:1160-1164
42. Andreas S, Heindl S, Wattky C, Moller K, Ruchel R (2000) Diagnosis of pulmonary aspergillosis using optical brighteners. Eur Respir J 15:407-411
43. Verweij PE, Mellado E, Melchers WJ (2007) Multiple-triazole-resistant aspergillosis. N Engl J Med 356:1481-1483
44. Collins J (2001) CT signs and patterns of lung disease. Radiol Clin North Am 39:1115-1135
45. Greene R (2005) The radiological spectrum of pulmonary aspergillosis. Med Mycol 43:S147-S154
46. Horger M, Einsele H, Schumacher U, Wehrmann M, Hebart H, Lengerke C, Vonthein R, Claussen CD, Pfannenberg C (2005) Invasive pulmonary aspergillosis: frequency and meaning of the "hypodense sign" on unenhanced CT. Br J Radiol 78:697-703
47. Kami M, Kishi Y, Hamaki T, Kawabata M, Kashima T, Masumoto T, Oki Y, Tanaka Y, Sawada S, Machida U, Ohtomo K, Kanda Y, Hirai H, Mutou Y (2002) The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients. Mycoses 45:287-294
48. Lee YR, Choi YW, Lee KJ, Jeon SC, Park CK, Heo JN (2005) CT halo sign: the spectrum of pulmonary diseases. Br J Radiol 78:862-865
49. Pasmans HL, Loosveld OJ, Schouten HC, Thunnissen F, van Engelshoven JM (1992) Invasive aspergillosis in immunocompromised patients: findings on plain film and (HR)CT. Eur J Radiol 14:37-40
50. Won HJ, Lee KS, Cheon JE, Hwang JH, Kim TS, Lee HG, Han J (1998) Invasive pulmonary aspergillosis: prediction at thin-section CT in patients with neutropenia - a prospective study. Radiology 208:777-782
51. Pinto PS (2004) The CT halo sign. Radiology 230:37-40
52. Greene RE, Schlamm HT, Stark P, Oestmann JW, Troke P, Patterson TF, Herbrecht R, Wingard J, Bennett JE, Lortholary J (2003) Radiological findings in acute invasive pulmonary aspergillosis: utility and reliability of halo sign and air crescent sign for diagnosis and treatment of invasive pulmonary aspergillosis in high-risk patients. Abstract European Congress of Microbiology and Infectious Diseases, 13th annual meeting
53. Maertens J, Verhaegen J, Lagrou K, Van EJ, Boogaerts M (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97:1604-1610
54. Maertens J, Van EJ, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M (2002) Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 186:1297-1306
55. Sulahian A, Boutboul F, Ribaud P, Leblanc T, Lacroix C, Derouin F (2001) Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 91:311-318
56. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu KL, Natarajan-Ame S, Lutz P, Dufour P, Bergerat JP, Candolfi E (2002) Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20:1898-1906
57. Pinel C, Fricker-Hidalgo H, Lebeau B, Garban F, Hamidfar R, Ambroise-Thomas P, Grillot R (2003) Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 41:2184-2186
58. Pfeiffer CD, Fine JP, Safdar N (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42:1417-1427
59. Sanguinetti M, Posteraro B, Pagano L, Pagliari G, Fianchi L, Mele L, La SM, Franco A, Fadda G (2003) Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbioll 41:3922-3925
60. Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA (2004) Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 42:5517-5522
61. Seyfarth HJ, Nenoff P, Winkler J, Krahl R, Haustein UF, Schauer J (2001) Aspergillus detection in bronchoscopically acquired material. Significance and interpretation. Mycoses 44:356-360
62. Clancy CJ, Jaber RA, Leather HL, Wingard JR, Staley B, Wheat LJ, Cline CL, Rand KH, Schain D, Baz M, Nguyen MH (2007) Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 45:1759-1765
63. Ansorg R, Van den Boom R, Rath PM (1997) Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 40:353-357
64. Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT, Bacigalupo A (2004) False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 38:913-916
65. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E (2004) Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 38:917-920
66. Mattei D, Rapezzi D, Mordini N, Cuda F, Lo NC, Musso M, Arnelli A, Cagnassi S, Gallamini A (2004) False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 42:5362-5363
67. Sulahian A, Touratier S, Ribaud P (2003) False-positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 349:2366-2367
68. Becker MJ, De MS, Fens MH, Verbrugh HA, Bakker-Woudenberg IA (2003) Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 52:428-434
69. Marr KA, Laverdiere M, Gugel A, Leisenring W (2005) Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40:1762-1769
70. Verweij PE, Latge JP, Rijs AJ, Melchers WJ, de Pauw BE, Hoogkamp-Korstanje JA, Meis JF (1995) Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. J Clin Microbiol 33:3150-3153
71. Maertens J, Theunissen K, Verbeken E, Lagrou K, Verhaegen J, Boogaerts M, Eldere JV (2004) Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 126:852-860
72. Salonen J, Lehtonen OP, Terasjarvi MR, Nikoskelainen J (2000) Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scand J Infect Dis 32:485-490
73. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH (2005) Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654-659
74. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D (2003) Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10:882-885
75. Skladny H, Buchheidt D, Baust C, Krieg-Schneider F, Seifarth W, Leib-Mosch C, Hehlmann R (1999) Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J Clin Microbiol 37:3865-3871
76. Bretagne S, Costa JM, Marmorat-Khuong A, Poron F, Cordonnier C, Vidaud M, Fleury-Feith J (1995) Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR. J Clin Microbiol 33:1164-1168
77. Raad I, Hanna H, Sumoza D, Albitar M (2002) Polymerase chain reaction on blood for the diagnosis of invasive pulmonary aspergillosis in cancer patients. Cancer 94:1032-1036
78. Raad I, Hanna H, Huaringa A, Sumoza D, Hachem R, Albitar M (2002) Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of Aspergillus in BAL. Chest 121:1171-1176
79. Buchheidt D, Baust C, Skladny H, Baldus M, Brauninger S, Hehlmann R (2002) Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol 116:803-811
80. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA (2006) The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 42:479-486
81. Hope WW, Walsh TJ, Denning DW (2005) Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 5:609-622
82. Garcia ME, Blanco JL, Caballero J, Gargallo-Viola D (2002) Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. J Clin Microbiol 40:1567-1568
83. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new "gold standard". Clin Infect Dis 37:415-425
84. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402-1407
85. Eriksson U, Seifert B, Schaffner A (2001) Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 322:579-582
86. Imhof A, Walter RB, Schaffner A (2003) Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 36:943-951
87. Andes D, Stamsted T, Conklin R (2001) Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 45:922-926
88. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764-771
89. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103:1527-1533
90. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL (1997) Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 41:1364-1368
91. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415
92. Bohme A, Ruhnke M, Buchheidt D, Karthaus M, Einsele H, Guth S, Heussel G, Heussel CP, Junghanss C, Kern WK, Kubin T, Maschmeyer G, Sezer O, Silling G, Sudhoff T, Szelenyi DH, Ullmann AJ (2003) Treatment of fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82:S133-S140
93. Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45:649-663
94. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT (2006) Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 79:362-370
95. Scherpbier HJ, Hilhorst MI, Kuijpers TW (2003) Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis 37:828-830
96. von Mach MA, Burhenne J, Weilemann LS (2006) Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 6:6
97. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D (2006) Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50:1570-1572
98. Robatel C, Rusca M, Padoin C, Marchetti O, Liaudet L, Buclin T (2004) Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. J Antimicrob Chemother 54:269-270
99. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL (2001) Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41:1159-1166
100. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA (2004) Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39:743-746
101. Marty FM, Cosimi LA, Baden LR (2004) Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350:950-952
102. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2-12
103. Denning DW (2003) Echinocandin antifungal drugs. Lancet 362:1142-1151
104. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563-1571
105. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, de Pauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402
106. Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32:358-366
107. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR (2000) Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine (Baltimore) 79:250-260
108. Lewis RE, Kontoyiannis DP (2001) Rationale for combination antifungal therapy. Pharmacotherapy 21:149S-164S
109. Kumar S, Chakrabarti R (2000) Amphotericin B both inhibits and enhances T-cell proliferation: inhibitory effect is mediated through H(2)O(2) production via cyclooxygenase pathway by macrophages. J Cell Biochem 77:361-371
110. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA (2003) Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97:1025-1032
111. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II (2003) Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292-299
112. Thiebaut A, Antal D, Breysse MC (2002) Refractory invasive fungal infections in patients with hematological malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California
113. Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del BR, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S (2006) Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81:320-326
114. Antoniadou A, Kontoyiannis DP (2003) Status of combination therapy for refractory mycoses. Curr Opin Infect Dis 16:539-545
115. Fluckiger U, Marchetti O, Bille J, Eggimann P, Zimmerli S, Imhof A, Garbino J, Ruef C, Pittet D, Tauber M, Glauser M, Calandra T (2006) Treatment options of invasive fungal infections in adults - review. Swiss Med Wkly 136:447-463
116. Kontoyiannis DP, Lewis RE (2003) Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 6:257-269